Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, shared a post on LinkedIn about recent paper published in The Lancet Oncology.
“Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas.
This Policy Review provides recommendations for the use of PET imaging in patients with gliomas and represents a joint effort of the Response Assessment in Neuro-Oncology (RANO) working group for PET and the European Association for Neuro-Oncology.”
Title: Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
Authors: Norbert Galldiks, Philipp Lohmann, Mariam Aboian, Ramon F. Barajas Jr., William G. Breen, Jana Ivanidze, Derek R. Johnson, Timothy J. Kaufmann, Michelle M. Kim, Maximilian J. Mair, Giuseppe Minniti, Michael Müther, Ali Nabavizadeh, Joshua D. Palmer, Roberta Rudà, Marion Smits, Nelleke Tolboom, Sophie E. M. Veldhuijzen van Zanten, Michael C. Veronesi, Jan-Michael Werner, Martin van den Bent, Susan M. Chang, Karl-Josef Langen, Ian Law, Jonathan McConathy, Minesh Mehta, Matthias Preusser, Susan C. Short, Riccardo Soffietti, Michael Vogelbaum, Michael Weller, Patrick Y. Wen, Joerg-Christian Tonn, Nathalie L. Albert
Read The Full Article at The Lancet Oncology.
More posts featuring Vivek Subbiah on OncoDaily.